Maria Learoyd

Maria Learoyd

UNVERIFIED PROFILE

Are you Maria Learoyd?   Register this Author

Register author
Maria Learoyd

Maria Learoyd

Publications by authors named "Maria Learoyd"

Are you Maria Learoyd?   Register this Author

17Publications

498Reads

20Profile Views

Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.

Clin Pharmacol Ther 2019 Jun 22;105(6):1492-1500. Epub 2019 Feb 22.

Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cpt.1338
Publisher Site
http://dx.doi.org/10.1002/cpt.1338DOI Listing
June 2019

Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.

Clin Pharmacokinet 2019 May;58(5):615-625

Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Boston, MA, 02451, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40262-018-0714-x
Publisher Site
http://dx.doi.org/10.1007/s40262-018-0714-xDOI Listing
May 2019

Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.

Cancer Chemother Pharmacol 2019 May 18;83(5):963-974. Epub 2019 Mar 18.

National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No. 17 Panjiayuan, Chaoyang District, Beijing, 100021, China.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-019-03799-1
Publisher Site
http://dx.doi.org/10.1007/s00280-019-03799-1DOI Listing
May 2019

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations.

Clin Pharmacol Ther 2019 01 9;105(1):229-241. Epub 2018 Aug 9.

Quantitative Clinical Pharmacology, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585620PMC
January 2019

In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.

Xenobiotica 2018 Jun 25;48(6):555-564. Epub 2017 Jul 25.

b Drug Metabolism and Pharmacokinetics, IMED Oncology, AstraZeneca , Cambridge , UK , and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00498254.2017.1346332DOI Listing
June 2018

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.

Eur J Cancer 2013 May 21;49(7):1521-9. Epub 2013 Feb 21.

Division of Hematology and Oncology, Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.01.013DOI Listing
May 2013